Omico
Omico
  • Industry
  • Researchers
  • Clinicians
  • Patients and Families
  • About Us
    • Our Programs
    • Our Network
    • Our Partners
    • Our Board
    • Our Leadership team
    • Publications
  • FAQ
Contact Us

Pages

  • About Us
    • Our Partners
    • Our Programs
      • Molecular Screening & Therapeutics (MoST) Study
        • MoST Substudies
      • Genetic Cancer Risk in the Young (RisC) study
      • Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+)
    • Our Network
      • Our sites
    • Our board
    • Leadership team
    • Publications
      • Annual reports
  • Clinicians
  • Contact Us
  • FAQ
  • Industry
  • News
  • Omico – Outsmarting Cancer Together
  • Patients and Families
  • Privacy Policy
  • Researchers
  • Sitemap

News

  • Making a difference
  • Masterclass webinar series - Demystifying the Molecular Tumour Board
  • How cancer develops resistance to treatment
  • A reflection on cancer
  • Australian Government & Roche co-fund the ‘ASPiRATION’ lung cancer study
  • Access to clinical trials crucial for Australians living with rare or uncommon cancers
  • Ground-breaking trial brings personalised treatments to those with rare cancers
  • Ground breaking trial
  • Privacy Policy
  • Omico is registered not for profit company
  • Sitemap
Omico Omico